Fortress Biotech (CNB0) Stock Overview

Operates as a biopharmaceutical company in the United States and internationally. More details

CNB0 fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	4/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 99.6% below our estimate of its fair value

Revenue is forecast to grow 36.81% per year

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 106.2% per year for the next 3 years

Volatile share price over the past 3 months compared to the German market

CNB0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW474,562 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

474,562 investors already sharing narratives

View all narratives

Fortress Biotech, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Fortress Biotech
Historical stock prices
Current Share Price	US$17.60
52 Week High	US$18.80
52 Week Low	US$5.00
Beta	1.21
1 Month Change	0.57%
3 Month Change	45.45%
1 Year Change	200.85%
3 Year Change	15.03%
5 Year Change	-18.52%
Change since IPO	-16.93%

Recent updates

Shareholder Returns

	CNB0	DE Biotechs	DE Market
7D	10.0%	0.8%	1.2%
1Y	200.9%	4.5%	0.7%

Return vs Industry: CNB0 exceeded the German Biotechs industry which returned 4.6% over the past year.

Return vs Market: CNB0 exceeded the German Market which returned 0.8% over the past year.

Price Volatility

Is CNB0's price volatile compared to industry and market?
CNB0 volatility
CNB0 Average Weekly Movement	10.4%
Biotechs Industry Average Movement	7.1%
Market Average Movement	5.4%
10% most volatile stocks in DE Market	12.8%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: CNB0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: CNB0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2006	78	Lindsay Rosenwald	www.fortressbiotech.com

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia.

Fortress Biotech, Inc. Fundamentals Summary

How do Fortress Biotech's earnings and revenue compare to its market cap?
CNB0 fundamental statistics
Market cap	€98.34m
Earnings (TTM)	€104.10m
Revenue (TTM)	€57.78m

0.9x

P/E Ratio

1.7x

P/S Ratio

Is CNB0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CNB0 income statement (TTM)
Revenue	US$66.16m
Cost of Revenue	US$30.86m
Gross Profit	US$35.31m
Other Expenses	-US$83.89m
Earnings	US$119.20m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	3.59
Gross Margin	53.36%
Net Profit Margin	180.16%
Debt/Equity Ratio	19.5%

How did CNB0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/29 20:17
End of Day Share Price	2026/07/29 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fortress Biotech, Inc. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Scott Henry	Alliance Global Partners
Stephen V. Byrne	BofA Global Research
Mayank Mamtani	B. Riley Securities, Inc.

Fortress Biotech (CNB0) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Fortress Biotech, Inc. Competitors

Novogenia

2invest

2invest

NKMAX

Price History & Performance

Recent News & Updates

Fortress Biotech, Inc. to Report Q1, 2026 Results on May 13, 2026

Fortress Biotech, Inc., Annual General Meeting, Jun 17, 2026

Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo

Fortress Biotech, Inc. and Cyprium Therapeutics, Inc. Announce FDA Acceptance of CUTX-101 NDA Resubmission

Fortress Biotech, Inc. to Report Q3, 2025 Results on Nov 12, 2025

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

Recent updates

Fortress Biotech, Inc. to Report Q1, 2026 Results on May 13, 2026

Fortress Biotech, Inc., Annual General Meeting, Jun 17, 2026

Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo

Fortress Biotech, Inc. and Cyprium Therapeutics, Inc. Announce FDA Acceptance of CUTX-101 NDA Resubmission

Fortress Biotech, Inc. to Report Q3, 2025 Results on Nov 12, 2025

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

Fortress Biotech, Inc. to Report Q2, 2025 Results on Aug 12, 2025

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 3000E Growth Index

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) completed the acquisition of Checkpoint Therapeutics, Inc. (NasdaqCM:CKPT) from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.

Fortress Biotech, Inc., Annual General Meeting, Jun 17, 2025

Fortress Biotech, Inc. Announces Resignation of Lucy Lu, M.D as from the Board of Directors

Fortress Biotech, Inc. to Report Fiscal Year 2024 Results on Mar 26, 2025

Fortress Biotech, Inc. and Helocyte, Inc. Announce First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $6.5 million.

Fortress Biotech, Inc. announced that it has received $1.500001 million in funding

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $128 million.

Fortress Biotech, Inc. announced that it expects to receive $50 million in funding

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Fortress Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $11 million.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Fortress Biotech Receives Second 180-Calendar Day Grace Period from Nasdaq to Regain Compliance with the Nasdaq Listing Rule 5550(a)(2)

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $13.896816 million.

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Fortress Biotech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Urica Therapeutics, Inc Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

Fortress Biotech, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Fortress Biotech Inc. Appoints David Jin as Chief Financial Officer

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 2000 Dynamic Index

Fortress Biotech, Inc.'s Subsidiary UR-1 Therapeutics, Inc. Doses First Patient in a Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

Fortress Biotech, Inc. to Report Q1, 2022 Results on May 10, 2022

Fortress Biotech, Inc., Annual General Meeting, Jun 21, 2022

Fortress Biotech, Inc. Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV